Reported 2 days ago
In a recent commentary, Jim Cramer labeled Kodiak Sciences Inc. (NASDAQ:KOD) as a 'pure spec stock' due to its significant financial losses and lack of profitability. The clinical-stage biopharmaceutical company is currently developing therapies for retinal diseases, but reported a net loss of $54.3 million in Q2 2025. While acknowledging its potential, Cramer suggested investors should be wary of its high-risk nature.
Source: YAHOO